PROVIDER POLICIES & PROCEDURES
|
|
- Blake Reed
- 8 years ago
- Views:
Transcription
1 PROVIDER POLICIES & PROCEDURES BRCA GENETIC TESTING The purpose of this document is to provide guidance to providers enrolled in the Connecticut Medical Assistance Program (CMAP) on the requirements for the prior authorization of BRCA Mutation Testing for breast and ovarian cancer susceptibility. This includes the applicable coverage guidelines and limitations for HUSKY Health Program members as well as the procedures for requesting authorization for these services. Genetic testing provides information that can be used to diagnose genetic diseases and susceptibility to diseases or conditions that are inherited. Such testing includes studying chromosomes to the level of individual genes, biochemical testing for the possible presence of genetic diseases, and identifying mutant forms of genes associated with increased risk of developing genetic disorders. The results of a genetic test can be used to confirm or rule out a genetic condition or to help determine an individual s chance of developing a genetic condition or passing on a genetic disorder. Results are often used to influence choices about health care and management of an identified genetic disorder or susceptibility to one. Several hundred genetic tests are currently available. The use of genetic testing for point mutations in the BRCA1 and BRCA2 genes may influence individual management in a variety of ways. Individuals with point gene mutation may consider increased surveillance for breast cancer, or consider a prophylactic mastectomy or oophorectomy. Family members of an individual with a known point mutation, who test negative for a mutation, can forego increased surveillance and/or consideration of prophylactic surgery. Genetic testing for point mutations BRCA1 and BRCA2 genes has emerged as a widely accepted test, when accompanied by genetic counseling. The BRACAnalysis Rearrangement Test (BART) is a refinement of the BRCA genetic tests and is purported to detect rare, large rearrangements of deoxyribonucleic acid (DNA) in the BRCA 1 and BRCA 2 genes which were previously undetected by standard genetic testing. The manufacturer (Myriad Genetic Laboratories) reports that BART testing will identify an additional approximate 3% of BRCA 1 and BRCA2 mutations in very high-risk families and is intended for use only in women at an exceptionally high risk for breast cancer who have previously tested negative for BRCA 1 and BRCA 2 sequence mutations. CLINICAL GUIDELINE Coverage guidelines for molecular testing for breast and/or ovarian cancer BRCA Mutation Testing will be made in accordance with the DSS definition of Medical Necessity and in line with published recommendations and guidelines disseminated by organizations including the U.S. Preventive Services Task Force, the American College of Medical Genetics, and the National Comprehensive Cancer Network. The following criteria are guidelines only. Coverage guidelines are based on an individual 1
2 assessment of the member and his or her clinical needs. Testing for the purpose of diagnosing a genetic disorder or identifying an individual member who is at risk for a late onset or slowly evolving genetic disorder may be considered clinically appropriate when: 1. A specific mutation or set of mutations has been identified and broadly accepted by credible medical societies to be reliably associated with the condition; and 2. The genetic disorder cannot be identified through biological or other testing; and 3. The member displays clinical features of or may be at increased risk of inheriting the mutation in question; and 4. The results of the genetic test would materially impact the medical management of the member with resulting improvement in health outcomes; and 5. Testing is accompanied by genetic counseling. BRCA Mutation Testing may be considered clinically appropriate for members who meet criteria in any one of the following categories: A. For individuals with a personal history of cancer, genetic testing for a BRCA1 or BRCA2 mutation, associated with genetic counseling, may be considered clinically appropriate when: 1. The individual has a history of breast cancer and at least 1 relative with breast cancer diagnosed prior to age 45; OR 2. The individual was diagnosed with breast cancer prior to age 50; OR 3. The individual has multiple primary breast cancers or bilateral breast cancer; OR 4. The individual is a male with breast cancer; OR 5. The individual has triple negative breast cancer diagnosed prior to age 60; OR 6. The individual has a history of breast cancer and 2 or more first-, second- or third-degree relatives with pancreatic cancer; OR 7. The individual has a history of ovarian, fallopian tube or primary peritoneal cancer; OR 8. The individual has a history of pancreatic cancer and 2 or more first-, second-, or third-degree relatives with breast and/or ovarian and/or pancreatic cancer; OR 9. The individual has a history of breast cancer and 2 or more first-, second- or third-degree relatives with breast or ovarian, fallopian tube, or primary peritoneal cancer; OR 10. The individual has a history of breast cancer and belongs to a population at risk for specific mutations due to ethnic background (for example, Ashkenazi Jewish, Icelandic, Swedish, Hungarian or Dutch descent). B. For individuals with a family history of cancer, genetic testing for a BRCA1 or BRCA2 mutation, associated with genetic counseling, may be clinically appropriate when they have a relative who would meet ANY of the following, but that relative is not available for testing: 1. The individual has a first- or second-degree relative with breast cancer who also had at least 1 relative with breast cancer diagnosed prior to age 45; OR 2. The individual has a first- or second-degree relative who had breast cancer diagnosed prior to age 50; OR 3. The individual has a first- or second-degree relative who had multiple primary breast cancers or bilateral breast cancer; OR 4. The individual has a first- or second-degree relative who has a history of ovarian, fallopian tube, or primary peritoneal cancer; OR 5. The individual has a first- or second-degree male relative who developed breast cancer; OR 2
3 6. The individual has a first- or second-degree relative who had triple negative breast cancer diagnosed prior to age 60; OR 7. The individual has a first- or second-degree relative with a history of breast cancer and 2 or more first-, second-, or third-degree relatives with pancreatic cancer; OR 8. The individual has a first- or second-degree relative who has a history of ovarian cancer and 2 or more first- second- or third-degree relatives with pancreatic cancer; OR 9. The individual has a first- or second-degree relative with a history of pancreatic cancer and 2 or more first-, second-, or third-degree relatives with breast and/or ovarian and/or pancreatic cancer. C. For individuals with a family history of 3 or more first-, second- or third-degree relatives with ovarian, fallopian tube or primary peritoneal cancer or breast cancer, (at least one of which has breast cancer at or before age 50), genetic testing for a BRCA1 or BRCA2 mutation, associated with genetic counseling, is generally considered clinically appropriate. D. Large genomic rearrangement testing (BART) to identify individuals at risk for BRCA1/2 related cancers is generally considered clinically appropriate for individuals who meet any of the criteria above for BRCA1/2 genetic sequence testing, but have negative results from that testing. Note: The U.S. Preventive Services Task Force recommends against routine referral for genetic counseling or routine breast cancer susceptibility (BRCA) testing for women whose family history is not associated with an increased risk for deleterious mutations in BRCA genes. NOTE: EPSDT Special Provision Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) is a federal Medicaid requirement that requires the Connecticut Medical Assistance Program (CMAP) to cover services, products, or procedures for Medicaid enrollees under 21 years of age where the service or good is medically necessary health care to correct or ameliorate a defect, physical or mental illness, or a condition identified through a screening examination. The applicable definition of medical necessity is set forth in Conn. Gen. Stat. Section 17b-259b (2011) [ref. CMAP Provider Bulletin PB ]. PROCEDURE Prior authorization of BRCA Mutation Testing is required. Coverage determinations will be based upon a review of requested and/or submitted case-specific information. Information Required for Review: 1. Fully completed State of Connecticut, Department of Social Services Outpatient Prior Authorization Request form or fully completed prior authorization request via web portal; and 2. Clinical information supporting the need for requested services to include pertinent clinical and family history; and 3. Other information as requested by CHNCT. Review Process: Requests for coverage of BRCA testing will be reviewed by CHNCT in accordance with procedures in place for reviewing requests for genetic testing. 3
4 Requesting Authorization: Requests for the prior authorization of BRCA testing must be submitted using the code specific to the test being requested (see table below). The code must be supported by the codes billed prior to January 2012 as stacked codes with the number of units for each. Example: Request made for CPT code unit Included on the prior authorization form are the supporting stacked codes with the number of units for each: # units # units # units # units # units Reimbursement: The code specific to the test requested (e.g ) will be priced at the sum of the Medicaid fees for the stacked codes in accordance with the listed per unit fee for each. EFFECTIVE DATE This Policy is effective for prior authorization requests for BRCA Mutation Testing for HUSKY Health Program members on or after January 1, LIMITATIONS Not Applicable CODES: Code Definition BRCA 1, BRCA 2 (breast cancer 1 and 2) (e.g., hereditary breast and ovarian cancer) gene analysis; full sequence analysis and common duplication/deletion variants in BRCA1 (i.e., exon 13 del 3.835kb, exon 13 dup 6kb, exon del 26kb, exon 22 del 510bp, exon 8-9 del 7.1kb) BRCA 1, BRCA 2 (breast cancer 1 and 2) (e.g., hereditary breast and ovarian cancer) gene analysis; 185delAG, 5385insC, 6174delT variants BRCA 1, BRCA 2 (breast cancer 1 and 2) (e.g., hereditary breast and ovarian cancer) gene analysis; uncommon duplication/deletion variants BRCA1 (breast cancer 1) (e.g., hereditary breast and ovarian cancer) gene analysis; full sequence analysis and common duplication/deletion variants (i.e., exon 13del 3.835kb, exon 13 dup 6kb, exon del 26kb, exon 22 del 510bp, exon 8-9 del 7.1kb BRCA1 (breast cancer 1) (e.g., hereditary breast and ovarian cancer) gene analysis; known familial variant BRCA2 (breast cancer 2) (e.g., hereditary breast and ovarian 4
5 Code Definition cancer) gene analysis; full sequence analysis BRCA2 (breast cancer 2) (e.g., hereditary breast and ovarian cancer) gene analysis; known familial variant DEFINITIONS 1. BRCA Genes: BRCA genes include cancer susceptibility gene 1 (BRCA1) and/or breast cancer susceptibility gene 2 (BRCA2). 2. Breast Cancer: A cancer starting in the cells of breast tissue in females and males; for the purpose of BRCA mutation testing including invasive or ductal carcinoma in situ. 3. Close Blood Relative: A 1 st degree relative (i.e., mother, sister, daughter); or a 2 nd degree relative (i.e., aunt, grandmother, niece); or a 3 rd degree relative (i.e., first cousin, great parent). 4. Current Procedural Terminology (CPT): The most recent edition of a listing, published by the American Medical Association, of descriptive terms and identifying codes for reporting medical services performed by providers. 5. HUSKY A: Connecticut children and their parents or a relative caregiver; and pregnant women may qualify for HUSKY A (also known as Medicaid). Income limits apply. 6. HUSKY B: Uninsured children under the age of 19 in higher income households may be eligible for HUSKY B (also known as the Children s Health Insurance Program) depending on their family income level. Family cost-sharing may apply. 7. HUSKY C: Connecticut residents who are age 65 or older or residents who are ages and who are blind, or have another disability, may qualify for Medicaid coverage under HUSKY C (this includes Medicaid for Employees with Disabilities (MED-Connect), if working). Income and asset limits apply. 8. HUSKY D: Connecticut residents who are ages without dependent children and who: (1) do not qualify for HUSKY A; (2) do not receive Medicare; and (3) are not pregnant, may qualify for HUSKY D (also known as Medicaid for the Lowest-Income populations). 9. HUSKY Health Program: The HUSKY A, HUSKY B, HUSKY C, HUSKY D and HUSKY Limited Benefit programs, collectively. 10. HUSKY Limited Benefit Program or HUSKY, LBP: Connecticut s implementation of limited health insurance coverage under Medicaid for individuals with tuberculosis or for family planning purposes and such coverage is substantially less than the full Medicaid coverage. 11. HUSKY Plus Physical Program (or HUSKY Plus Program): A supplemental physical health program pursuant to Conn. Gen. Stat. 17b-294, for medically eligible members of HUSKY B in Income Bands 1 and 2, whose intensive physical health needs cannot be accommodated within the HUSKY Plan, Part B. 12. Medically Necessary or Medical Necessity: (as defined in Connecticut General Statutes 17b- 259b) Those health services required to prevent, identify, diagnose, treat, rehabilitate or ameliorate an individual's medical condition, including mental illness, or its effects, in order to attain or maintain the individual's achievable health and independent functioning provided such services are: (1) Consistent with generally-accepted standards of medical practice that are defined as standards that are based on (A) credible scientific evidence published in peerreviewed medical literature that is generally recognized by the relevant medical community, (B) recommendations of a physician- specialty society, (C) the views of physicians practicing in relevant clinical areas, and (D) any other relevant factors; (2) clinically appropriate in terms of type, frequency, timing, site, extent and duration and considered effective for the individual's illness, injury or disease; (3) not primarily for the convenience of the individual, the individual's health care provider or other health care providers; (4) not more costly than an alternative 5
6 service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the individual's illness, injury or disease; and (5) based on an assessment of the individual and his or her medical condition. 13. Ovarian Cancer: Ovarian cancer is a cancer of the ovary. For the purpose of BRCA mutation testing it includes both fallopian tube and primary peritoneal carcinoma. 14. Prior Authorization: A process for approving covered services prior to the delivery of the service or initiation of the plan of care based on a determination by CHNCT as to whether the requested service is medically necessary. ADDITIONAL RESOURCES AND REFERENCES: American Medical Association, Current Procedural Terminology Manual: 2014 DSS Provider Bulletin : Consolidated Laboratory Fee Schedule Update, dated June 2012 U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility. Agency for Healthcare Research and Quality: Rockville, MD; September American College of Medical Genetics (ACMG). Genetic susceptibility to breast and ovarian cancer: Assessment, counseling and testing guidelines. ACMG: Bethesda, MD; National Comprehensive Cancer Network (NCCN). Genetic/familial high-risk assessment: breast and ovarian. NCCN Clinical Practice Guidelines in Oncology. V PUBLICATION HISTORY Status Date Action Taken Original publication October 2012 Reviewed December 2013 Clinical Quality Sub-Committee Review. Reference updated. These changes approved at the December 16, 2013 Clinical Quality Sub-Committee meeting. Reviewed December 2014 Clinical Quality Sub-Committee Review Reference updated. Change approved at the December 15, 2014 Clinical Quality Sub-Committee meeting. Updated August 2015 HUSKY Program definitions updated at request of DSS. 6
PROVIDER POLICIES & PROCEDURES
PROVIDER POLICIES & PROCEDURES HOMEMAKER-HOME HEALTH AIDE MEDICATION ADMINISTRATION SERVICES The purpose of this policy is to provide guidance to providers enrolled in the Connecticut Medical Assistance
More informationPROVIDER POLICIES & PROCEDURES
PROVIDER POLICIES & PROCEDURES REHABILITATION SERVICES The primary purpose of this document is to assist providers enrolled in the Connecticut Medical Assistance Program (CMAP Providers) with the information
More informationThe Department of Vermont Health Access Medical Policy
State of Vermont Department of Vermont Health Access 312 Hurricane Lane, Suite 201 [Phone] 802-879-5903 Williston, VT 05495-2807 [Fax] 802-879-5963 www.dvha.vermont.gov Agency of Human Services The Department
More informationPROVIDER POLICIES & PROCEDURES
PROVIDER POLICIES & PROCEDURES SCLEROTHERAPY TREATMENT OF SUPERFICIAL VARICOSE VEINS OF THE LEGS The purpose of this document is to provide guidance to providers enrolled in the Connecticut Medical Assistance
More informationpatient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015
patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015 BRCA1 and BRCA2 Mutations Cancer is a complex disease thought to be caused by several different factors. A few types of cancer
More informationGenetic Testing for Susceptibility to Breast and Ovarian Cancer (BRCA1 and BRCA 2)
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. M issouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationMEDICAL POLICY SUBJECT: GENETIC TESTING FOR HEREDITARY BRCA MUTATIONS. POLICY NUMBER: 2.02.06 CATEGORY: Laboratory Test
MEDICAL POLICY SUBJECT: GENETIC TESTING FOR, 10/15/15 PAGE: 1 OF: 12 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical
More informationif your family has a history
if your family has a history OF CANCER. put it to the test. Learn about your risk for hereditary and ovarian and how you can reduce it. do you have a family history of Breast or Ovarian Cancer? what does
More informationPROVIDER POLICIES & PROCEDURES
PROVIDER POLICIES & PROCEDURES PATIENT LIFT SYSTEMS The purpose of this document is to provide guidance to providers enrolled in the Connecticut Medical Assistance Program (CMAP) on the requirements for
More informationMedical Policy Manual. Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer. Date of Origin: January 27, 2011
Medical Policy Manual Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer Date of Origin: January 27, 2011 Section: Genetic Testing Last Reviewed Date: May 2015 Policy No: 02 Effective Date:
More informationHereditary Breast Cancer Panels. High Risk Hereditary Breast Cancer Panel Hereditary Breast/Ovarian/Endometrial Cancer Panel
P A T I E N T G U I D E Hereditary Breast Cancer Panels High Risk Hereditary Breast Cancer Panel Hereditary Breast/Ovarian/Endometrial Cancer Panel B a y l o r M i r a c a G e n e t i c s L a b o r a t
More informationpatient guide BRCA1 and BRCA2 Genetic Testing for Hereditary Breast and Ovarian Cancer
patient guide BRCA1 and BRCA2 Genetic Testing for Hereditary Breast and Ovarian Cancer What is hereditary cancer? Cancer affects many people in the U.S.: breast cancer affects 1 in 8 women and ovarian
More informationBRCA1 & BRCA2: Genetic testing for hereditary breast and ovarian cancer patient guide
BRCA1 & BRCA2: Genetic testing for hereditary breast and ovarian cancer patient guide What is Hereditary? Breast cancer is the most common cancer in women in the U.S. (it affects about 1 in 8 women). Ovarian
More informationGENETIC CONSIDERATIONS IN CANCER TREATMENT AND SURVIVORSHIP
GENETIC CONSIDERATIONS IN CANCER TREATMENT AND SURVIVORSHIP WHO IS AT HIGH RISK OF HEREDITARY CANCER? Hereditary Cancer accounts for a small proportion of all cancer or approximately 5-10% THE DEVELOPMENT
More informationName of Policy: Genetic Testing for Hereditary Breast and/or Ovarian Cancer
Name of Policy: Genetic Testing for Hereditary Breast and/or Ovarian Cancer Policy #: 513 Latest Review Date: January 2014 Category: Laboratory Policy Grade: B Background/Definitions: As a general rule,
More informationBreast Cancer s Link to Ovarian Cancer: It s in Your Genes. foundationforwomenscancer.org
Breast Cancer s Link to Ovarian Cancer: It s in Your Genes foundationforwomenscancer.org There are now more than 2.6 million women in America who have been diagnosed with breast cancer. A very small fraction
More informationAdvice about familial aspects of breast cancer and epithelial ovarian cancer a guide for health professionals DECEMBER 2010
Advice about familial aspects of breast cancer and epithelial ovarian cancer a guide for health professionals DECEMBER 2010 This guide has three parts: 1. Information for health professionals 2. Tables
More informationPatient Support Guide
Patient Support Guide to genetic testing for hereditary breast and ovarian cancer syndrome Testing for BRCA1 and BRCA2 is available from Quest Diagnostics. Quest Diagnostics Patient Support Guide to Genetic
More informationGenetic Testing for Hereditary Breast and Ovarian Cancer - BRCA1/2 ANALYSIS -
Genetic Testing for Hereditary Breast and Ovarian Cancer - BRCA1/2 ANALYSIS - January 2005 SCIENTIFIC BACKGROUND Breast cancer is considered to be one of the most prevalent cancer in women. The overall
More informationScreenWise. Breast, Cervical, and Hereditary Cancer Screenings OCTOBER 28, 2015
ScreenWise Breast, Cervical, and Hereditary Cancer Screenings OCTOBER 28, 2015 ScreenWise Three programs working together to bring quality screening services to Oregon residents Why we all do this work
More informationPrevention GENEration. The Importance of Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (HBOC)
הסיכוי שבסיכון PREVENTION GENERATION Prevention GENEration The Importance of Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (HBOC) We thank Prof. Ephrat Levy-Lahad Director, Medical
More informationIs it time for a new drug development paradigm?
Is it time for a new drug development paradigm? Robert McDonough, M.D. Senior Director, Clinical Policy Research and Development 1 The Aetna Way Our Cause To make quality health care more affordable and
More informationBreast Cancer Screening
Breast Cancer Screening Summary of the Clinical Practice Guideline September 2013 These recommendations are systematically developed statements to assist practitioner and patient decisions about appropriate
More informationGenetic Testing for Hereditary Breast/ Ovarian Cancer Syndrome (BRCA1/BRCA2)
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Genetic Testing for Hereditary Breast/ Ovarian Cancer Syndrome
More informationGENETIC TESTING FOR INHERITED MUTATIONS OR SUSCEPTIBILITY TO CANCER OR OTHER CONDITIONS MED207.110
GENETIC TESTING FOR INHERITED MUTATIONS OR SUSCEPTIBILITY TO CANCER OR OTHER CONDITIONS MED207.110 COVERAGE: Pre- and post-genetic test counseling may be eligible for coverage in addition to the genetic
More informationAre You at Risk for Ovarian Cancer?
Are You at Risk for Ovarian Cancer? A Woman s Guide Read this brochure to learn more about ovarian cancer symptoms, risk factors and what you can do to reduce your risk. ALL WOMEN HAVE SOME RISK OF OVARIAN
More informationOvarian Cancer Genetic Testing: Why, When, How?
Ovarian Cancer Genetic Testing: Why, When, How? Jeffrey Dungan, MD Associate Professor Division of Clinical Genetics Department of Obstetrics & Gynecology Northwestern University Feinberg School of Medicine
More informationHereditary Ovarian cancer: BRCA1 and BRCA2. Karen H. Lu MD September 22, 2013
Hereditary Ovarian cancer: BRCA1 and BRCA2 Karen H. Lu MD September 22, 2013 Outline Hereditary Breast and Ovarian Cancer (HBOC) BRCA1/2 genes How to identify What it means to you What it means to your
More informationInsurance Protections and Coverage
Insurance Protections and Coverage The First Line of Defense: Application of Breast Cancer Genomics Standards in Primary Care Friday, February 21, 2014 Presenter: Lisa K. Liang, Esq. Health Law Unit (Breast
More informationIMMEDIATE HOT LINE: Effective March 2, 2015
MEDICARE COVERAGE OF LABORATORY TESTING Please remember when ordering laboratory tests that are billed to Medicare/Medicaid or other federally funded programs, the following requirements apply: 1. Only
More informationNOTTINGHAM UNIVERSITY HOSPITAL NHS TRUST NOTTINGHAM BREAST INSTITUTE BREAST AND OVARIAN FAMILY HISTORY GUIDELINES
NOTTINGHAM UNIVERSITY HOSPITAL NHS TRUST NOTTINGHAM BREAST INSTITUTE BREAST AND OVARIAN FAMILY HISTORY GUIDELINES GP Referrals All GP referrals for asymptomatic women with a family history of breast and/or
More informationNational Medical Policy
National Medical Policy Subject: Policy Number: Genetic Testing for BRCA1 and BRCA2 NMP136 Effective Date*: April 2004 Updated: September 2015 This National Medical Policy is subject to the terms in the
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): May 20, 2014 Effective Date: December 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationUSPTO Roundtable Written Commentary
USPTO Roundtable Written Commentary In response to this committee s request for quantitative data, FORCE has gathered information from sources including healthcare providers, the hereditary breast and
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
BRCA1 and BRCA2 Testing Page 1 of 30 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: BRCA1 and BRCA2 Testing Pre-Determination of Services IS REQUIRED by the Member
More informationBRCA Genes and Inherited Breast and Ovarian Cancer. Patient information leaflet
BRCA Genes and Inherited Breast and Ovarian Cancer Patient information leaflet This booklet has been written for people who have a personal or family history of breast and/or ovarian cancer that could
More informationBRCA1 & BRCA2 GeneHealth UK
BRCA1 & BRCA2 GeneHealth UK BRCA1 & BRCA2 What is hereditary breast cancer? Cancer is unfortunately very common, with 1 in 3 people developing cancer at some point in their lifetime. Breast cancer occurs
More informationBreast cancer and genetics
Breast cancer and genetics Cancer and genes Our bodies are made up of millions of cells. Each cell contains a complete set of genes. We have thousands of genes. We each inherit two copies of most genes,
More informationINTERVENTIONS BREAST CANCER GENETICS YOUNG BREAST CANCER SURVIVORS
INTERVENTIONS BREAST CANCER GENETICS YOUNG BREAST CANCER SURVIVORS AND THEIR AT-RISK RELATIVES Maria C. Katapodi, PhD, RN, FAAN Professor of Nursing Faculty of Medicine, University of Basel, Switzerland
More informationUnderstanding Hereditary Breast and Ovarian Cancer. Maritime Hereditary Cancer Service
Understanding Hereditary Breast and Ovarian Cancer Maritime Hereditary Cancer Service General Information Cancer is very common. About one in three (33%) people are diagnosed with some form of cancer during
More informationCancer: Genetic testing can save lives
Cancer: Genetic testing can save lives Track chances of having a tumor's tendency among people with a history of disease cases in the family, but practice should not be trivialized and hurt even more who
More informationThe Genetics of Early- Onset Breast Cancer. Cecelia Bellcross, Ph.D., M.S.,C.G.C. Department of Human Genetics Emory University School of Medicine
The Genetics of Early- Onset Breast Cancer Cecelia Bellcross, Ph.D., M.S.,C.G.C. Department of Human Genetics Emory University School of Medicine All cancers are genetic BUT Not all cancers are hereditary
More informationLesson Plan: Genetic Testing and Hereditary Cancer
Lesson Plan: Genetic Testing and Hereditary Cancer OVERVIEW This lesson plan is designed to be used with the film In the Family, which explores issues related to genetic testing and the difficult decisions
More informationBRCA1 and BRCA2. BRCA1 and BRCA2 Clinician Guide KNOWING WHAT TO LOOK FOR KNOWING WHERE TO LOOK AND KNOWING WHAT IT MEANS
BRCA1 and BRCA2 BRCA1 and BRCA2 Clinician Guide KNOWING WHAT TO LOOK FOR KNOWING WHERE TO LOOK AND KNOWING WHAT IT MEANS BRCA1 and BRCA2 Breast cancer is the most common cancer in women, diagnosed in
More informationBRCA in Men. Mary B. Daly,M.D.,Ph.D. June 25, 2010
BRCA in Men Mary B. Daly,M.D.,Ph.D. June 25, 2010 BRCA in Men Inheritance patterns of BRCA1/2 Cancer Risks for men with BRCA1/2 mutations Risk management recommendations for men with BRCA1/2 mutations
More informationContents. molecular biology techniques. - Mutations in Factor II. - Mutations in MTHFR gene. - Breast cencer genes. - p53 and breast cancer
Contents Introduction: biology and medicine, two separated compartments What we need to know: - boring basics in DNA/RNA structure and overview of particular aspects of molecular biology techniques - How
More informationHereditary Breast and Ovarian Cancer (HBOC)
Oxford University Hospitals NHS Trust Oxford Regional Genetic Department Hereditary Breast and Ovarian Cancer (HBOC) Information for women with an increased lifetime risk of breast and ovarian cancer What
More informationGuidance Document Enhancing cancer genomics practice through education, surveillance and policy Introductions
Guidance Document Enhancing cancer genomics practice through education, surveillance and policy Introductions Georgians of all backgrounds have experienced the devastating impact of cancer. It is the second
More informationBreast cancer in families. This booklet explains what a family history of breast cancer is, and what this may mean for you or your family.
Breast cancer in families This booklet explains what a family history of breast cancer is, and what this may mean for you or your family. Worried Lorem about ipsum breast dolore cancer estes Contents
More informationNumber 12.04.516 Effective Date August 11, 2015 Revision Date(s) Replaces 2.04.133 (not adopted)
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDI HISTORY Genetic Testing for CHEK2 Mutations for Breast Cancer Number 12.04.516
More informationCommon Cancers & Hereditary Syndromes
Common Cancers & Hereditary Syndromes Elizabeth Hoodfar, MS, LCGC Regional Cancer Genetics Coordinator Kaiser Permanente Northern California Detect clinical characteristics of hereditary cancer syndromes.
More informationFamilial Breast Cancer Referrals and Risk Management
Familial Breast Cancer Referrals and Risk Management Presented by: Helen Mountain Genetic Counsellor Genetic Services of WA Perth (KEMH and PMH) Joondalup Rockingham Bunbury Geraldton Kalgoorlie Albany
More informationImpact of Breast Cancer Genetic Testing on Insurance Issues
Impact of Breast Cancer Genetic Testing on Insurance Issues Prepared by the Health Research Unit September 1999 Introduction The discoveries of BRCA1 and BRCA2, two cancer-susceptibility genes, raise serious
More informationHereditary Breast Cancer. Nicole Kounalakis, MD Assistant Professor of Surgery University of Colorado Medical Center
Hereditary Breast Cancer Nicole Kounalakis, MD Assistant Professor of Surgery University of Colorado Medical Center Outline Background Assessing risk of patient Syndromes BRCA 1,2 Li Fraumeni Cowden Hereditary
More informationGenetics and Breast Cancer. Elly Lynch, Senior Genetic Counsellor Manager, Austin Health Clinical Genetics Service
Genetics and Breast Cancer Elly Lynch, Senior Genetic Counsellor Manager, Austin Health Clinical Genetics Service Overview Background/Our Team What is the difference between sporadic/familial cancer? How
More informationHereditary Breast and Ovarian Cancer (HBOC) Syndrome Testing Criteria*
Breast Cancer Gene 1 and 2 (BRCA) Benefits t Change fr Texas Medicaid Effective July 1, 2015 Infrmatin psted May 15, 2015 Nte: This article applies t claims submitted t TMHP fr prcessing. Fr claims prcessed
More informationUnderstanding Your Risk of Ovarian Cancer
Understanding Your Risk of Ovarian Cancer A WOMAN S GUIDE This brochure is made possible through partnership support from Project Hope for Ovarian Cancer Research and Education. Project HOPE FOR OVARIAN
More informationHEREDITARY BRCA1. Faulty gene INFORMATION LEAFLET. How Do I Reduce My Risk?
HEREDITARY BREAST CANCER BRCA1 Faulty gene INFORMATION LEAFLET How Do I Reduce My Risk? Page 1 CONTENTS Part A 1 What is BRCA1 2 How does BRCA1 affect a person s risk of cancer? 3Testing for BRCA1 4Benefits
More informationIf you are signing for a minor child, you refers to your child throughout the consent document.
CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY Adult Patient or Parent, for Minor Patient INSTITUTE: National Cancer Institute PRINCIPAL INVESTIGATOR: Raffit Hassan, M.D. STUDY TITLE: Tissue Procurement
More informationCancer Genetic Counseling
Cancer Genetic Counseling Guest Expert: Ellen, MS Director of the Yale Cancer Center Cancer Genetic Counseling Program www.wnpr.org www.yalecancercenter.org I am Bruce Barber and this is Yale Cancer Center
More informationDelivering the Promise of Genetic and Genomic Medicine. From Research to Clinical Care:
A m e r i c a n C o l l e g e o f M e d i c a l G e n e t i c s a n d G e n o m i c s Tr a n s l a t i n g G e n e s I n t o H e a l t h From Research to Clinical Care: Delivering the Promise of Genetic
More informationUtah Data as of July 2003. Mental Health and Substance Abuse Services in Medicaid and SCHIP in Utah
Mental Health and Substance Abuse Services in Medicaid and SCHIP in Utah As of July 2003, 196,600 people were covered under Utah s Medicaid/SCHIP programs. There were 157,322 enrolled in the Medicaid program,
More informationPatient Information. for Childhood
Patient Information Genetic Testing for Childhood Hearing Loss Introduction This document describes the most common genetic cause of childhood hearing loss and explains the role of genetic testing. Childhood
More informationGenetic Testing in Research & Healthcare
We Innovate Healthcare Genetic Testing in Research & Healthcare We Innovate Healthcare Genetic Testing in Research and Healthcare Human genetic testing is a growing science. It is used to study genes
More informationConnecticut Data as of July 2003
Mental Health and Substance Abuse Services in Medicaid and SCHIP in Connecticut As of July 2003, 378,961 people were covered under Connecticut Medicaid/SCHIP programs. There were 364,692 enrolled in the
More informationThe following information is only meant for people who have been diagnosed with advanced non-small cell
Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC
More informationBenefits Collaborative Policy Statement WOMEN S HEALTH SERVICES
Page 1 uf 5 The services listed below are not inclusive of all services available to women on Medicaid, but WOMEN S HEALTH SERVICES Benefits Collaborative Policy Statement Women s health services are preventative
More informationOregon Survey Instrument
Oregon Survey Instrument Cancer Genetic Insurance Questions for Insurers Q1a. Do you have written policies on your coverage of cancer genetic testing, counseling, and follow-up procedures for breast and
More informationHereditary Breast Cancer Testing. Diagnostic
Hereditary Cancer Testing Diagnostic New solutions for hereditary breast cancer. Identifying and understanding the genetic contribution to breast cancer allows for individualized disease management and
More informationMaryland Data as of July 2003. Mental Health and Substance Abuse Services in Medicaid and SCHIP in Maryland
Mental Health and Substance Abuse Services in Medicaid and SCHIP in Maryland As of July 2003, 638,662 people were covered under Maryland's Medicaid/SCHIP programs. There were 525,080 enrolled in the Medicaid
More informationGENETICS AND GENOMICS IN NURSING PRACTICE SURVEY
GENETICS AND GENOMICS IN NURSING PRACTICE SURVEY Dear Registered Nurse: You are invited to take a survey that will evaluate primary issues in genetics and genomics. As the front line of care, nurses have
More informationUNIT 13 (OPTION) Genetic Abnormalities
Unit 13 Genetic Abnormailities 1 UNIT 13 (OPTION) Genetic Abnormalities Originally developed by: Hildur Helgedottir RN, MN Revised (2000) by: Marlene Reimer RN, PhD, CCN (C) Associate Professor Faculty
More informationIllinois Insurance Facts Illinois Department of Insurance Coverage for the Diagnosis and Treatment of Breast Conditions
Illinois Insurance Facts Illinois Department of Insurance Coverage for the Diagnosis and Treatment of Breast Conditions Revised May 2015 Note: This information was developed to provide consumers with general
More informationA survey conducted by Ovarian Cancer Australia: A report summarising findings on a family history and genetic testing survey
1 P a g e A survey conducted by Ovarian Cancer Australia: A report summarising findings on a family history and genetic testing survey Executive Summary Introduction Ovarian Cancer Australia (OCA) surveyed
More information6/10/2015. Hereditary Predisposition for Breast Cancer: Looking at BRCA1/BRCA2 Testing & Beyond. Hereditary Cancers. BRCA1 and BRCA2 Review
Hereditary Predisposition for Breast Cancer: Looking at BRCA1/BRCA2 Testing & Beyond Arturo Anguiano MD, FACMG International Medical Director, Medical Affairs Vice Chairman, Genetics; Medical Director,
More informationHighlights of the Florida Medicaid Ambulatory Surgical Center Services Coverage and Limitations Handbook
Highlights of the Florida Medicaid Ambulatory Surgical Center Services Coverage and Limitations Handbook Agency for Health Care Administration July 2013 1 Learning Objectives Provide an overview of the
More informationChapter 4 Health Care Management Unit 1: Care Management
Chapter 4 Health Care Unit 1: Care In This Unit Topic See Page Unit 1: Care Care 2 6 Emergency 7 4.1 Care Healthcare Healthcare (HMS), Highmark Blue Shield s medical management division, is responsible
More informationInitial Preventive Physical Examination
Initial Preventive Physical Examination Overview The Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003 expanded Medicare's coverage of preventive services. Central to the Centers
More informationPROVIDER BULLETIN No. 05-05
PROVIDER BULLETIN No. 05-05 February 15, 2005 TO: FROM: BY: RE: Speech Therapy Providers Mary Steiner, Interim Administrator, Medicaid Division Marsha Rekart, Program Specialist Medicaid coverage of speech
More informationClinical Significance of Large Rearrangements in BRCA1 and BRCA2
Original Article Clinical Significance of Large Rearrangements in BRCA1 and BRCA2 Thaddeus Judkins, BS; Eric Rosenthal, PhD; Christopher Arnell, MBA; Lynn Anne Burbidge, BS; Wade Geary, BA; Toby Barrus,
More informationYour Jewish Genes. Hereditary Breast Cancer and Ovarian Cancer
E D U C A T I O N A L B O O K L E T S E R I E S Your Jewish Genes Hereditary Breast Cancer and Ovarian Cancer 2011 Sharsheret, Inc. All rights reserved. 07/11 3000 Your Jewish Genes Hereditary Breast Cancer
More informationHAVE YOU BEEN NEWLY DIAGNOSED with DCIS?
HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? Jen D. Mother and volunteer. Diagnosed with DCIS breast cancer in 2012. An educational guide prepared by Genomic Health This guide is designed to educate women
More informationHow to Code Well-Care Visits for Children and Adolescents
How to Code Well-Care Visits for Children and Adolescents to meet NCQA s HEDIS Quality Goals and Receive Appropriate Reimbursement and Credit for Providing Quality Care TABLE OF CONTENTS Introduction...
More informationMedicare Coverage of Genomic Testing
Medicare Coverage of Genomic Testing Louis B. Jacques, MD Director, DID/CAG/OCSQ With acknowledgements to Jeff Roche, MD Social Security Act 1862(a)(1)(A) Notwithstanding any other provision of this title,
More informationIntegration of Genetic and Familial Data into. Electronic Medical Records and Healthcare Processes
Integration of Genetic and Familial Data into Electronic Medical Records and Healthcare Processes By Thomas Kmiecik and Dale Sanders February 2, 2009 Introduction Although our health is certainly impacted
More informationSummary of Cancer Prevention and Screening Benefits of the Affordable Care Act (ACA) in Kentucky for health professionals
Summary of Cancer Prevention and Screening Benefits of the Affordable Care Act (ACA) in Kentucky for health professionals Talk with patients about ü Potential benefits, harms, and unknowns of cancer ü
More informationBreast Cancer: from bedside and grossing room to diagnoses and beyond. Adriana Corben, M.D.
Breast Cancer: from bedside and grossing room to diagnoses and beyond Adriana Corben, M.D. About breast anatomy Breasts are special organs that develop in women during puberty when female hormones are
More informationQuestions & Answers on ACA Section 4106 Improving Access to Preventive Services for Eligible Adults in Medicaid
Questions & Answers on ACA Section 4106 Improving Access to Preventive Services for Eligible Adults in Medicaid STATE PLAN AMENDMENT (SPA) Q1. Can a state submit a SPA to implement section 4106 at any
More informationWhat Is Genetic Counseling? Helping individuals and families understand how genetics affects their health and lives
What Is Genetic Counseling? Helping individuals and families understand how genetics affects their health and lives What does the career involve? Explore family histories to identify risks Reducing risks
More informationICD-10 Diagnostic Coding for. Breast Reconstruction
ICD-10 Diagnostic Coding for Webinar Hosted by: Breast Reconstruction December 5, 2013 Presented by: Kim Pollock, RN, MBA, CPC Meet Kim Pollock RN, MBA, CPC Kim Pollock, RN, MBA, CPCspecializes in streamlining
More informationGenetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Evidence Synthesis
Evidence Synthesis Number 37 Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Evidence Synthesis Prepared for: Agency for Healthcare Research and Quality
More information256B.055 ELIGIBILITY CATEGORIES.
1 MINNESOTA STATUTES 2013 256B.055 256B.055 ELIGIBILITY CATEGORIES. Subdivision 1. Children eligible for subsidized adoption assistance. Medical assistance may be paid for a child eligible for or receiving
More informationCHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA
CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA Cytogenetics is the study of chromosomes and their structure, inheritance, and abnormalities. Chromosome abnormalities occur in approximately:
More informationU.K. Familial Ovarian Cancer Screening Study (UK FOCSS) Phase 2 Patient Information Sheet
U.K. Familial Ovarian Cancer Screening Study (UK FOCSS) Phase 2 Patient Information Sheet 1. Invitation You are being invited to take part in a research study. Before you decide it is important for you
More informationPrognosis for Healthcare: The Future of Medicine
Prognosis for Healthcare: The Future of Medicine Bruce M. Cohen, M.D., Ph.D. Director, Frazier Research Institute, McLean Hospital President and Psychiatrist in Chief Emeritus, McLean Hospital Robertson-Steele
More informationFlorida Data as of July 2003. Mental Health and Substance Abuse Services in Medicaid and SCHIP in Florida
Mental Health and Substance Abuse Services in Medicaid and SCHIP in Florida As of July 2003 2,441,266 people were covered under Florida's Medicaid and SCHIP programs. There were 2,113,820 enrolled in the
More informationHUSKY A Parent Transition. Prepared for MAPOC November 13, 2015
HUSKY A Parent Transition Prepared for MAPOC November 13, 2015 June Special Session, Public Act No. 15-5 Effective August 1, 2015. Reduces the HUSKY A Income Limit for Parents and Caretaker Relatives from
More informationPremera s definition of Medical Necessity is written in your PREMERAFirst Provider Contract Part 1.08.
Premera and the Washington State Chiropractic Association (WSCA) worked closely to release the following positions focused on several issues centered on the practice of chiropractic care in the state of
More informationBREAST CANCER AWARENESS FOR WOMEN AND MEN by Samar Ali A. Kader. Two years ago, I was working as a bedside nurse. One of my colleagues felt
Ali A. Kader, S. (2010). Breast cancer awareness for women and men. UCQ Nursing Journal of Academic Writing, Winter 2010, 70 76. BREAST CANCER AWARENESS FOR WOMEN AND MEN by Samar Ali A. Kader Two years
More informationDEPARTMENT OF SOCIAL SERVICES AUDIT PROTOCOL PHYSICIAN SERVICES UPDATED FEBRUARY 1, 2015
DEPARTMENT OF SOCIAL SERVICES AUDIT PROTOCOL PHYSICIAN SERVICES UPDATED FEBRUARY 1, 2015 Listed are the most common audit findings noted for physician services provided under the State Medicaid program,
More information